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1. Introduction
Osteoporosis is a common skeletal disorder that is 
accompanied by a decrease in bone mass, deterioration of 
bone microstructures, and an increase in susceptibility to 
fracture (1). Osteoporosis has a complex etiology and is 
considered to be a multifactorial polygenic disease with 
genetic factors alongside hormonal, environmental, and 
nutritional ones contributing to its incidence (2).
Fracture leads to increases in morbidity and mortality 
and imposes high costs on individuals and society. On 
average, one of every three women and one of every 12 
men develop fractures during their lifetime (3,4).
One of the conditions causing osteoporosis is a 
postmenopausal decrease in estrogen. After 35 years, the 
amount of bone density gradually declines in both men and 
women, but since estrogen decreases in postmenopausal 
women, their bone mass declines more rapidly compared 
to men, so that 5–10 years after menopause one third of 
the bone density is lost. In ages over 65 years, the amount 
of bone loss equalizes in women and men and bone mass 
continues to decline until death (1,5). Genetic differences 
are likely to have a role in bone mineral density (BMD) 
diversity in different ethnicities (6).
An extracellular matrix is the main component of bone 
and develops a scaffolding and three-dimensional network 
from collagen type I, on which minerals precipitate (7). 
Collagen is a fibrous protein that comprises about 30% of 
body weight and is frequently seen in connective tissues 
like bones, tendons, and skin. This protein has an important 
contribution to wound healing, cell proliferation, cell 
differentiation, and cell migration. Proteins of the collagen 
family are the most frequent proteins of the extracellular 
matrix (8,9).
Collagen type I is the main collagen and the highest 
protein in the bone matrix, comprising approximately 80% 
of the total bone tissue’s proteins. Variations in collagen 
characteristics and the relative amount in the bone matrix 
could influence the mechanical properties of the bone 
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tissue and cause fragility and increased susceptibility to 
fracture. Collagen consists of two chains, alpha 1 and alpha 
2 (at a 2:1 ratio in the collagen fibers), which are encoded 
by two different genes, collagen type 1α1 (COLIA1) and 
collagen type 1α2 (COLIA2) (10–12). The gene COLIA1 
is on the long arm of chromosome 17 (17q21–22) and has 
51 exons; the gene COLIA2 is on chromosome 7 and has 
52 exons (13). An imbalanced ratio of collagen chains 
could be a potential risk factor for bone fragility and a 
predisposing factor for osteoporosis (12).
Different polymorphisms have been described in several 
genes (14). Although many studies have been conducted 
to date, the unique contributions of each one of these 
polymorphisms to osteoporosis pathogenesis have still 
remained unconfirmed worldwide (15).
COLIA1 and COLIA2 mutations are accompanied by 
bone collagen disorders and severe clinical phenotypes 
including osteogenesis imperfecta. A substitution 
mutation of G/T in intron 1 of gene COLIA1 (rs 1800012, 
G>T substitution) probably influences gene transcription, 
resulting in a variation in the alpha 1 sequence/alpha 2 
sequence ratio and collagen adult protein; this is called 
COLIA1 Sp1 polymorphism (16,17).
The genotypes of COLIA1 Sp1 consist of SS, Ss, and 
ss. Allele s inheritance is recessive. The presence of allele 
s increases the tendency toward Sp1 transcription factor. 
The ratio of collagen α1(I) to α2(I) was 2.3 to 1 in Ss 
heterozygotes compared with the expected value of 2 to 1 in 
SS homozygotes (18). (For osteoblasts of homozygous SS, the 
alpha 1/alpha 2 ratio is similar to the rate in question, i.e. 2 
to 1). The variation in the alpha sequence ratios is due to the 
increase in mRNA COLIA1 compared to mRNA COLIA2. 
As a result, the strength of a heterozygous Ss individual’s 
bone declines in comparison to one with homozygous SS. 
Homozygous ss has the least bone density with a higher risk 
of fracture. Of course, this polymorphism is more associated 
with vertebral and wrist fractures. In gene COLIA1, there 
are other polymorphisms that are associated with bone 
density, including PCOL2, which causes G/T substitution in 
the promoter region (12,17,19).
Recent advances in detecting the genetic basis of 
diseases have opened new horizons, and disease diagnosis 
through determining genotype is gradually increasing. 
The pharmacologic and interventional methods for 
preventing osteoporosis in the individuals at risk 
add to the significance of the issue. Different studies 
have demonstrated the association of COLIA1 Sp1 
polymorphism with bone density rate (20), but no such 
association has been specified in Iranians. Since no study, 
to the best of our knowledge, has yet been done on the 
association of osteoporosis having a molecular basis with 
this polymorphism, this study aimed to investigate the 
association between Sp1 polymorphism and bone density 
rate in women aged 45 and over in an accessible Iranian 
subpopulation.
2. Materials and methods
In this descriptive, analytical study conducted between 
December 2012 and September 2013, blood samples were 
taken for bone density measurement from women aged 45 
and over in referring centers in southwestern Iran, based 
on convenience sampling.
In this study, the age of 45 was regarded as the age of 
onset of menopausal changes (21).
 In this study, 200 samples were investigated. Sample 
size was calculated using the Cochran equation. Exclusion 
criteria included corticosteroid consumption history, 
ovariectomization or premature ovarian failure, thyroid 
disease, calcium intake disorders, and gastrointestinal and 
renal diseases.
After consent was obtained from the participants and 
questionnaires related to clinical data were filled out, a 5 
mL sample of peripheral blood was taken from each patient 
and put in tubes containing EDTA (0.5 M). The blood 
samples were sent to the Cellular and Molecular Research 
Center of Shahrekord University of Medical Sciences for 
molecular analysis. For this, DNA was extracted using the 
phenol–chloroform method (22). The quality, quantity, 
concentration, and purity of the extracted DNA were 
examined by spectrophotometry.
The chain relevant to the collagen 1 gene was 
extracted from the NCBI database (23). The primers for 
Sp1 polymorphism were designed using Primer3, which 
examines the primers in terms of primer–dimer formation 
or their self-supplementation and provides the operator 
with the best chain. The primers used are shown in Table 1.
Polymorphism proliferation was done by polymerase 
chain reaction (PCR). In the present study, for proliferation 
Table 1. The primer chains used in this study.
5´–3´ primer sequencesPrimer typeTm
CTGGACTATTTGCGGACTTTTTGGF70
GGCGAGGGAGGAGAGAAGR160
GTCCAGCCCTCATCCTGGCCR268
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of the regions in question and PCR conduction, firstly the 
main reaction solution was prepared in a microtube (vial). 
At this step, the DNA sample was not added to the solution. 
After distributing the solution among the special PCR vials, 
we added the necessary amount of DNA sample to them. 
In each PCR analysis, a vial was regarded as a negative 
control that indicated lack of material contamination with 
the DNA sample. The final volume of reaction solution was 
considered to be 25 µL in each microtube. A thermocycler 
(PC818, ASTEC, Japan) was used.
For separation, identification, and purification of the 
DNA fragments, an electrophoresis technique on 8% 
polyacrylamide gel was used with TBE and loading X6 
(Fermentas) buffers (24). The fragments were dissolved 
using restriction enzymes (Fermentas). The detection 
of DNA size was done with a ready-to-use GeneRulerTM 
DNA ladder. Silver nitrate staining was used to observe the 
obtained bands. The data were analyzed using SPSS with 
the chi-square and analysis of variance (ANOVA) tests.
3. Results
Considering that all women over 45 years old have 
some proportion of bone density decline, we assigned 
the individuals with normal bone density and/or mild 
osteopenia as the control group (comprising 70 individuals) 
and those with severe osteopenia and osteoporosis as the 
patient group (consisting of 130 individuals), based on 
radiograph t-scores  (Table 2). In this study, a t-score > 
–1 was determined as normal, a t-score ≤ –1 to ≥ –2 
as mild osteopenia, a t-score < –2 to ≥ –2.5 as severe 
osteopenia, and a t-score < –2.5 as osteoporosis (25).
To investigate the quality and quantity of the extracted 
DNA, NanoDrop was used. In most cases, the quality 
of the extracted DNA samples was desirable and had an 
A260/A280 value between 1.75 and 2. 
For Sp1 polymorphism, the PCR reaction is a 
seminested type; that is, through the first step of the 
PCR, the fragment containing Sp1 polymorphism is 
proliferated. The size of the fragments yielded by PCR 
of the Sp1 polymorphism gene COLIA1 in the first step 
was 287 bp; the second PCR was conducted on the 287 
bp product obtained from the first PCR and the cutting 
site was developed using the second PCR. The size of the 
fragments obtained from the second PCR was 254 bp. 
From enzymatic dissolution of Sp1 polymorphism of the 
collagen gene by enzyme restrictor MscI, two fragments of 
18 and 236 bp were developed. The 18 bp fragment had a 
high speed because of its small size and it is not observed 
in Figure 1.
Genotype and allele frequency were calculated for the 
polymorphism in question in the two groups. To examine 
the difference in genotypic frequency between the patients 
and the control group, chi-square and ANOVA tests were 
used. The confidence interval (CI) was set to 95% in all 
experiments and P < 0.05 was considered significant 
(Tables 3 and 4).
The chi-square test was independently calculated for 
the patients and control group with a degree of freedom of 
2 for the polymorphism in question. The P value for Sp1 
polymorphism in the patients was calculated as 0; that is, 
statistically there was a significant deviation for the Sp1 
polymorphism and no Hardy–Weinberg equilibrium was 
noted (P = 0.001, χ2 = 34.25). In the control group, the P 
value obtained was 0.266; that is, in the control group there 
was no significant deviation for Sp1 polymorphism and a 
Hardy–Weinberg equilibrium was seen (P = 0.226, χ2 = 
2.97).
The ANOVA test indicated a significant difference in 
the Sp1 polymorphism between the control group and the 
patients.
Table 2. Characteristics of the control and patient groups in this study.
Variable Mean ± SD(patients)
Mean ± SD
(control group) P value
Number 130 70
Lumbar vertebrae t-score 2.8- ± 0.67 0.9- ± 0.8 < 0.0001
Femoral neck t-score 1.3- ± 0.78 0.34- ± 0.5 < 0.0001
Age (years) 59.9 ± 8.4 51.3 ± 5.7 < 0.0001
Height (cm) 154.8 ± 3.6 158.5 ± 4.9 < 0.0001
Weight (kg) 66.3 ± 8.09 71.7 ± 9.1 < 0.0001
Lumbar vertebrae BMD* (g/cm2) 0.73 ± 0.1 0.92 ± 0.15 < 0.0001
Femoral neck BMD (g/cm2) 0.76 ± 0.1 0.88 ± 0.11 < 0.0001
* = Bone mineral density.
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Figure 1. A: PCR product of Sp1 polymorphism in the second step (the size of the 
proliferated section was 254 bp). B: The results relevant to enzymatic dissolution of 
Sp1 polymorphism. M = DNA size marker, C+ = positive control, and C– = negative 
control. The samples numbered 1 and 3 have homozygous genotype ss, the samples 
numbered 2 and 5 have homozygous genotype SS, and the samples numbered 4, 6, 
7, 8, 9, and 10 have heterozygous genotype Ss.
Table 3. Sp1 genotype and allele frequency in the two groups.
Sp1 polymorphism
of the collagen gene
Genotypic frequency
OR (95% CI) P value
Control group Patients
Genotypes
SS 40 (57.1%) 12 (9.2%) 2.69 (1.47–4.93) <0.0001
Ss 22 (31.4%) 98 (75.4%) 0.64 (0.32–1.29) 0.17
ss 8 (11.4%) 20 (15.4%) 1.00
Total 70 (100) 130 (100%)
Alleles
Allelic frequency
S 0.73 (73%) 0.47 (47%) 1.80 (1.28–2.53) <0.0001
s 0.27 (27%) 0.53 (53%) 1.00
Total 1 (100%) 1 (100%)
Table 4. The number of expected and observed individuals for Sp1 polymorphism in the two groups.
Sp1 polymorphism
of the collagen gene
Patients OR
(95% CI)
P value
Control group OR
(95% CI)
P value
observed expected observed expected
Genotypes
SS 12 28.7 0.82 (0.45–1.48) 0.52 40 37.3 0.84 (0.52–1.36) 0.54
Ss 98 64.8 1.68 (1.16–2.44) 0.003 22 27.6 0.71 (0.42–1.22) 0.41
ss 20 36.5 1.00 8 5.1 1.00
Total 130 130 70 70
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The mean t-score for the lumbar vertebrae was –2.425 in 
12 patients with genotype SS, –2.761 in 98 with genotype Ss, 
and –3.395 in 20 patients with genotype ss. The df for both 
lumbar vertebrae and femoral neck was 2 while the P value 
for lumbar vertebrae was 0.00 and that of femoral neck 0.007, 
indicating that the Sp1 polymorphism was significantly 
associated with t-score, i.e. bone density. The individuals 
with genotype SS had the highest density, followed by the 
individuals with genotypes ss and Ss (Table 5).
4. Discussion
Polymorphism or multiformity is a change in nucleotides 
in a gene sequence that leads to no particular disease and 
has a frequency of higher than 1% in the communities. 
In fact, this polymorphism can develop or destroy an 
enzyme’s identifying site and develop various genotypes 
(26). The results of the present study highlight that Sp1 
polymorphism is an important index for low bone mass 
and vertebrae fracture and determining the genotypes of 
this polymorphism is likely to be valuable in identifying 
the women at risk of osteoporosis (27).
Different studies on the association of polymorphism 
of several genes with osteoporosis have been conducted, 
including the vitamin D receptor gene, collagen type 
1, calcitonin receptor, insulin-like growth factor, and 
interleukin 6 (28).
In the present study, the association of Sp1 
polymorphism of the collagen gene with bone density 
was investigated in women aged 45 and older. In view of 
the obtained results, homozygous ss and heterozygous 
Ss individuals had the lowest t-scores, lower in the 
homozygous ss individuals compared to the heterozygous 
Ss. There is a significant association between bone 
density and Sp1 polymorphism of the collagen gene and 
a statistically considerable difference in genotype and 
allelic frequency was observed between the patients and 
the control group (P < 0.05). In the patients with severe 
osteoporosis and vertebral fracture, genotypes ss and Ss 
are prevalent (approximately 54%) (29,30).
 In the present study, older patients were shorter and 
thinner and the BMD of these individuals was lower 
compared to the control group. Some other researchers 
obtained similar results. For example, in a study on British 
women, this polymorphism was associated with BMD. As 
such, BMD in the homozygous genotype SS was higher 
than in the heterozygous genotype Ss and the homozygous 
genotype ss (29).
Langdahl et al. investigated the association of Sp1 
polymorphism of the collagen gene osteoporosis-
associated fractures in Danish men and women and found 
that Sp1 polymorphism of COLIA1 was notably associated 
with lumbar vertebral fractures in both men and women 
(31).
Inconsistent findings have been obtained on the 
association between Sp1 polymorphism of the collagen 
gene and osteoporosis-related fractures in Caucasian 
postmenopausal women (32–35). The results of four meta-
analyses in this field indicated that Sp1 polymorphism 
of COLIA1 gene is associated with osteoporosis-related 
fractures and BMD in Caucasian postmenopausal women 
(18,27,36,37). This polymorphism contributes importantly 
to osteoporosis pathogenesis, which is mediated by affecting 
BMD and other predictors of osteoporosis-associated risk 
of fracture such as the ultrasound characteristics of bone 
and skeletal geometry (38).
One of the above meta-analyses is indicative of an 
association between the presence of the s allele of Sp1 
polymorphism and a decline in BMD of the lumbar 
vertebrae and femoral neck, and an increase in vertebral 
fracture (36). Ralston et al. argued that fracture risk in 
individuals with the homozygous ss genotype was about 
40% higher than that in those with the genotype SS (39). 
Ji et al. conducted a study on menopausal Caucasian 
women and concluded that Sp1 polymorphism was likely 
to be associated with osteoporotic fracture (40). A study 
in Turkey indicated that bone density in the individuals 
with genotype Ss was lower compared to those with 
genotype SS (41), consistent with the present study. Some 
Table 5. The relationship between Sp1 polymorphism and t-score.
Genotypes Number T-score(Mean ± SD) Standard error P value
Lumbar 
vertebrae 
SS
Ss
ss
12
98
20
–2.425 ± 0.48
–2.761 ± 0.64
–3.395 ± 0.62
0.13
0.06
0.13
0.001
Femoral
neck
SS
Ss
ss
12
98
20
–1.250 ± 0.55
–1.300 ± 0.81
–1.850 ± 0.55
0.16
0.08
0.12
0.007
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researchers have obtained opposite results. For example, 
in a study of postmenopausal Swedish women, Liden 
et al. argued that COLIA1 Sp1 polymorphism was not 
significantly associated with femoral neck BMD, but closely 
associated with vertebral fracture (42). In an investigation 
by McClean et al. in Northern Ireland, osteoporosis-
associated fractures and Sp1 were not associated (43). 
Bandres et al. investigated the association between BMD 
and COLIA1 in Spanish postmenopausal women and 
stated that although no association was found between 
COLIA1 and BMD, this gene was significantly associated 
with the prevalence of osteoporotic fractures. This should 
be examined in a larger sample size (44). The association 
between osteoporosis and Sp1 polymorphisms (COLIA1) 
in postmenopausal women in Turkey was investigated 
and no statistically considerable difference in genotype 
and allelic frequency was observed between the patients 
and the control group (45). As stated by Bandres et al., in 
studies in which opposite results were obtained, a small 
sample size was offered as the reason. The other reason 
for this inconsistency could be the study of different races. 
In view of the numerous potentially identifiable genetic 
markers and clinical outcomes to which these may be 
related, testing and validation of statistical hypotheses in 
genetic epidemiology is an unprecedented task (27).
Since collagen I has numerous polymorphisms, it 
is recommended that the association of other collagen I 
polymorphisms with bone density be examined to achieve 
a complete haplotype. The association of bone density with 
other polymorphisms involved in osteogenesis regulation 
should be studied as well.
Sp1 gene polymorphism is associated with bone 
density rate in women aged 45 and over, more commonly 
observed in homozygosity. Determining this genotype’s 
polymorphism is valuable to identify the women at risk of 
developing osteoporosis.
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